Sooma has secured €5 million in funding to advance its innovative alternative treatment solutions for depression, with investments led by Voima Ventures and participation from Verge HealthTech Fund and Stephen Industries.
Information on the Target
Sooma is a pioneering healthcare company focused on developing innovative treatments for mental health disorders, specifically targeting depression. By leveraging advanced therapeutic techniques and cutting-edge research, the company aims to provide alternatives to conventional medication, thereby enhancing the quality of life for patients suffering from mental health challenges.
This recent funding round of €5 million will enable Sooma to advance its research and development efforts, pursue clinical trials, and expand its product offerings. The investment is a crucial stepping stone towards establishing a robust platform for long-term growth and market presence within the mental health sector.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in the Target's Specific Country
The mental health landscape in Europe has experienced significant shifts over the past few years, primarily driven by increasing awareness of mental health issues and a growing emphasis on alte
Similar Deals
Fåhraeus Startup & Growth FSG Fund II → Aplagon Oy
2025
Voima Ventures
invested in
Sooma
in 2024
in a Seed Stage deal
Disclosed details
Transaction Size: $5M